{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-165903","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.465045+00:00","generated_at":"2026-06-01T02:52:19.730266+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Crinetics enters ATM equity offering agreement for up to $350M","bullets":["Filed prospectus supplement registering up to $350M in common stock sales.","Agents Leerink Partners and Cantor Fitzgerald will receive 3.0% commission per share sold.","No minimum sales required; sales made via 'at-the-market' methods under Rule 415.","Agreement dated June 21, 2024; no escrow or trust arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-165903","json":"https://secwatch.observer/filing/0001193125-24-165903.json","markdown":"https://secwatch.observer/filing/0001193125-24-165903.md","text":"https://secwatch.observer/filing/0001193125-24-165903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/0001193125-24-165903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/d781699d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:52:19.730266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}